{Reference Type}: Journal Article
{Title}: PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer.
{Author}: Wang C;Liu L;Li X;Lei J;Li Y;Shen Z;Shi H;Cheng Y;
{Journal}: Future Oncol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 3
{Factor}: 3.674
{DOI}: 10.1080/14796694.2024.2342241
{Abstract}: Aim: The prognosis of high-risk, locally advanced cervical cancer (LACC) remains poor following concurrent chemoradiotherapy (CCRT). We investigated whether the effect of CCRT can be enhanced by programmed cell death protein 1 (PD-1) inhibitor. Methods: A retrospective cohort study was conducted to compare the efficacy and safety of CCRT group (n = 82) and PD-1 inhibitor plus CCRT group (n = 70). Results: Compared with the CCRT group, the PD-1 inhibitor plus CCRT group had significantly higher objective response rate, median progression-free survival, leukopenia and fatigue. The addition of PD-1 inhibitor to CCRT showed a favorable trend in overall survival without statistical significance. Conclusion: PD-1 inhibitor plus CCRT presented a significant survival benefit and a manageable safety profile in high-risk LACC.<BR>[Box: see text].